| Visit 1 | Daily | Visit 2 | Visit 3 | Visit 4 | Weekly Phone Calls | Visit 5 |
---|---|---|---|---|---|---|---|
Screening (within 60 days of baseline) | Days (−7 to 70) | Baseline Week 0 | Week 3 | Week 6 | Week (−1, 1–2, 4–5 & 7–9) | Week 10 | |
Laboratory Values 1 | X | Â | Â | Â | Â | Â | Â |
Medical Exam/History/Socio-demographics | X | Â | Â | Â | Â | Â | Â |
Urine Pregnancy Test 1 | X | Â | Â | Â | Â | Â | Â |
PRIME-MD2 | X | Â | Â | Â | Â | Â | Â |
HADS 2 | X | Â | Â | Â | X | Â | X |
BFI 2 | X | Â | X | X | X | X | X |
Concomitant Medication & Supplements | X | Â | Â | Â | Â | Â | Â |
Sleep Diary | X | Â | Â | Â | X | Â | Â |
Group Randomization 3 | Â | Â | X | Â | Â | Â | Â |
Actiwatch Data Collected | Â | X | X4 | X4 | X4 | Â | X4 |
LTQL | Â | Â | X | Â | X | Â | X |
BSAPQ 2 | X | Â | X | Â | X | Â | X |
GSE 2 | Â | Â | X | Â | X | Â | X |
BPI2 | X | Â | X | Â | X | Â | X |
Study Logbook | Â | X | X | X | X | Â | X |
PSQI 2 | X | Â | Â | Â | X | Â | X |
VAS for Pain 2 | X | Â | Â | Â | Â | Â | Â |
Berlin Questionnaire | X | Â | Â | Â | Â | Â | Â |
Therapy Evaluation Questionnaire | Â | Â | X | Â | X | Â | Â |
Perform Acupressure 5 | Â | Â | X | X | X | Â | Â |
Assess Treatment Fidelity – Self efficacy Measure |  |  |  | X | X |  |  |
Adverse Events | Â | Â | Â | X | X | X | X |
Assessment of Blinding | Â | Â | Â | Â | X | Â | Â |